These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2456096)

  • 21. Iloprost binding and inhibition of aggregation in platelet rich plasma. Differences between normal and type IIa hypercholesterolemic subjects.
    Oliva DW; Maderna P; Accomazzo MR; Nicosia S; Tremoli E
    Biochem Pharmacol; 1989 Jan; 38(1):39-45. PubMed ID: 2462881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Desensitization of prostacyclin responsiveness in a neuronal hybrid cell line: selective loss of high affinity receptors.
    Leigh PJ; MacDermot J
    Br J Pharmacol; 1985 May; 85(1):237-47. PubMed ID: 2992650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The intrainfusion rebound platelet activation during continuous prostaglandin I2 infusion occurs at the receptor level.
    Sinzinger H; Steurer G; Fitscha P; Kraupp O
    Prog Clin Biol Res; 1987; 242():19-23. PubMed ID: 2444986
    [No Abstract]   [Full Text] [Related]  

  • 24. Prostacyclin receptor expression on platelets of humans with type 2 diabetes is inversely correlated with hemoglobin A1c levels.
    Knebel SM; Sprague RS; Stephenson AH
    Prostaglandins Other Lipid Mediat; 2015; 116-117():131-5. PubMed ID: 25617843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The putative prostacyclin receptor antagonist (FCE-22176) is a full agonist on human platelets and NCB-20 cells.
    Wilkins AJ; MacDermot J
    Eur J Pharmacol; 1986 Aug; 127(1-2):117-9. PubMed ID: 2428638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel subtype of the prostacyclin receptor expressed in the central nervous system.
    Takechi H; Matsumura K; Watanabe Y; Kato K; Noyori R; Suzuki M; Watanabe Y
    J Biol Chem; 1996 Mar; 271(10):5901-6. PubMed ID: 8621463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute reversible reduction of PGI2 platelet receptors after iloprost infusion in man.
    Modesti PA; Fortini A; Poggesi L; Boddi M; Abbate R; Gensini GF
    Thromb Res; 1987 Dec; 48(6):663-9. PubMed ID: 2448896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decrease of prostaglandin I2 binding sites in thyroid cancer.
    Virgolini I; Hermann M; Sinzinger H
    Br J Cancer; 1988 Nov; 58(5):584-8. PubMed ID: 2464364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Age related changes of platelet prostacyclin receptors in humans.
    Modesti PA; Fortini A; Abbate R; Gensini GF
    Eur J Clin Invest; 1985 Aug; 15(4):204-8. PubMed ID: 2995049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet PGI2-receptor behaviour change after treatment with acetylsalicylic acid in healthy volunteers.
    Böhm T; Virgolini I; Sinzinger H
    Agents Actions Suppl; 1992; 37():197-203. PubMed ID: 1632294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Agonist-dependent phosphorylation of an epitope-tagged human prostacyclin receptor.
    Smyth EM; Nestor PV; FitzGerald GA
    J Biol Chem; 1996 Dec; 271(52):33698-704. PubMed ID: 8969241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Desensitization of prostacyclin responsiveness in platelets. Apparent differences in the mechanism in vitro or in vivo.
    MacDermot J
    Biochem Pharmacol; 1986 Aug; 35(16):2645-9. PubMed ID: 2427086
    [No Abstract]   [Full Text] [Related]  

  • 33. The platelet rebound phenomenon during PGI2-infusion occurs at the receptor level.
    Steurer G; Fitscha P; Sinzinger H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):435-8. PubMed ID: 2465947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Binding of an 125I-labeled thromboxane A2/prostaglandin H2 receptor antagonist to washed canine platelets.
    Mais DE; Kochel PJ; Saussy DL; Halushka PV
    Mol Pharmacol; 1985 Aug; 28(2):163-9. PubMed ID: 2991736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Competitive antagonism at thromboxane receptors in human platelets.
    Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
    Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Homologous desensitization of human platelet thromboxane A2/prostaglandin H2 receptors.
    Okwu AK; Ullian ME; Halushka PV
    J Pharmacol Exp Ther; 1992 Jul; 262(1):238-45. PubMed ID: 1378092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis of a new chemically and metabolically stable prostacyclin analogue with high and long-lasting oral activity.
    Skuballa W; Schillinger E; Stürzebecher CS; Vorbrüggen H
    J Med Chem; 1986 Mar; 29(3):313-5. PubMed ID: 2419560
    [No Abstract]   [Full Text] [Related]  

  • 38. Induction of prostacyclin receptor expression in human erythroleukemia cells.
    Murray R; Furci L; FitzGerald GA
    FEBS Lett; 1989 Sep; 255(1):172-4. PubMed ID: 2477277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence of the residues involved in ligand recognition in the second extracellular loop of the prostacyclin receptor characterized by high resolution 2D NMR techniques.
    Ruan KH; Wu J; So SP; Jenkins LA
    Arch Biochem Biophys; 2003 Oct; 418(1):25-33. PubMed ID: 13679079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Binding of a thromboxane A2/prostaglandin H2 receptor antagonist to washed human platelets.
    Mais DE; Burch RM; Saussy DL; Kochel PJ; Halushka PV
    J Pharmacol Exp Ther; 1985 Dec; 235(3):729-34. PubMed ID: 3001275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.